The winding path of MS progression

How the biological processes cause progression in different types of MS.

Siponimod offers hope for people with secondary progressive MS

A new, international clinical trial has shown that siponimod can slow progression in people with secondary progressive MS.

Antidepressant drug may treat Progressive MS

Screening of almost 250 medications has identified clomipramine as a possible treatment for progressive MS.

First treatment for early primary progressive MS approved in Europe

The European Commission has approved the first disease-modifying therapy, ocrelizumab, for early primary progressive MS (PPMS).

European Medicines Agency recommends market authorisation for ocrelizumab (Ocrevus) in EU

The EMA has recommended that ocrelizumab (Ocrevus), the first disease-modifying treatment for primary progressive MS (PPMS), be prescribed for adults with early primary progressive MS

First treatment licensed for primary progressive MS in the US

Ocrelizumab has been approved as a treatment for both relapsing and primary progressive MS in the US

People affected by MS helping to steer research in progressive MS

Video from Caroline Sincock who recently joined the International Progressive MS Alliance

What happened at ECTRIMS 2016?

Researchers and health professionals gather for the latest updates and research findings on treatment, care and management of MS

Second Scientific Congress of the International Progressive MS Alliance

Challenges and next steps considered

Intrathecal Rituximab is not effective in progressive multiple sclerosis

A recent study has failed to show any benefit for Rituximab in people with secondary progressive MS